2-OH(E1+E2) / 2-MeO(E1+E2) Ratio

If you're looking at an estrogen metabolite report, this ratio describes the balance between two groups of estrogen breakdown products leaving your body in urine. Its use for preventive care remains exploratory. Studies haven't established that changing this number reduces cancer risk or improves hormonal health.

The calculation adds 2-hydroxyestrone and 2-hydroxyestradiol, then divides that total by the sum of 2-methoxyestrone and 2-methoxyestradiol. These compounds are measured in a 24-hour urine collection using LC-MS/MS. This method separates and identifies the compounds before their amounts are used in the calculation. The ratio itself has no units.

Two Steps in Estrogen Breakdown

Your liver and other tissues process estrone and estradiol through several routes. One adds a chemical group at position 2 on the estrogen molecule, producing the 2-hydroxy forms. The COMT enzyme can then convert these into 2-methoxy forms through methylation. Methylation is the addition of a small carbon-based chemical group.

Both groups appear in urine. Their relative amounts depend on how much is produced, how the compounds are converted into other forms, and how they're excreted. A higher ratio means more 2-hydroxy products relative to 2-methoxy products in the sample. It doesn't establish that estrogen is accumulating inside you or quantify the percentage your body has successfully cleared.

The methoxy products have biological effects of their own. In cell experiments, 2-methoxyestradiol inhibited the growth of cells that form blood vessels. Giving it to mice also suppressed tumor growth. Those findings help explain scientific interest in this pathway, but they don't show that increasing its urinary concentration or lowering this ratio prevents cancer in people.

What the Breast Cancer Research Measures

Much of the research concerns the entire 2-hydroxylation pathway, individual metabolites, or ratios with different ingredients. Many studies also use serum or plasma rather than urine. Those distinctions matter: a larger share of estrogen passing through the 2-pathway is a different measurement from the balance between its hydroxy and methoxy products.

These studies differ in their populations, specimens, calculations, and timing. Their results don't support a simple rule that more 2-hydroxy estrogen is always favorable or that a lower hydroxy-to-methoxy ratio is always healthier. Research on methylation of the separate 4-hydroxylation pathway also cannot establish the meaning of this 2-pathway ratio.

Urine and breast tissue are different biological samples. A small study comparing them in women with breast cancer found important differences in their estrogen profiles. It did not validate this urinary ratio as a measure of COMT activity or estrogen exposure within breast tissue.

Body Weight and Other Hormone Research

In more than 1,800 postmenopausal women from the Women's Health Initiative, body weight was associated with serum estrogen patterns. Among women who weren't currently using menopausal hormone therapy, higher BMI generally accompanied higher estrogen concentrations. After accounting for estradiol, higher BMI was associated with lower concentrations of some methylated 2-pathway products. That finding doesn't establish how body weight changes this combined urine ratio, or whether weight loss would move it in a predictable direction.

Bone studies have examined related urinary measurements. In one study of postmenopausal women, the 2-hydroxyestrone-to-16α-hydroxyestrone ratio was associated with subsequent bone loss, and urinary 2-methoxyestrone was associated with bone density. Neither measurement was this ratio. These findings don't establish a target that balances breast health against bone health.

Women with polycystic ovary syndrome had lower urinary 2-hydroxy estrogens in a small study using first-void urine. A separate tissue comparison within that study found more COMT protein in affected ovaries, which suggested a possible explanation but didn't prove faster estrogen methylation. Research in preeclampsia found changes in individual estrogen metabolites in plasma. Neither study validated this 24-hour urine ratio for diagnosing or monitoring those conditions.

Inherited variation can affect the components too. Premenopausal women carrying the CYP3A7*1C variant had lower concentrations of several 2-pathway metabolites in spot urine. Because both hydroxy and methoxy products were affected, that result doesn't establish a desirable direction for this ratio.

When Results Can Be Misleading

• Incomplete collection or poor storage: missing urine, collecting for the wrong duration, or failing to follow storage instructions can distort the sample.
• Menstrual cycle timing: a small study using 24-hour urine found that several estrogen metabolites changed across the cycle. Comparing different phases can mix ordinary hormonal variation with other changes.
• Pregnancy: individual hydroxy and methoxy metabolites change during pregnancy. A small cross-sectional study found different patterns at different gestational stages, including a mid-pregnancy peak followed by a decline in 2-methoxyestrone. It doesn't support treating this ratio as a steadily improving measure of estrogen clearance.
• Hormone medications and supplements: these can change the underlying estrogen profile. Results obtained during different regimens describe different hormonal conditions.
• Very small component values: when the methoxy total is close to the assay's detection limit, small measurement differences can produce a large change in the ratio. A component below detection may prevent a reliable calculation.
• Differences between assays: LC-MS/MS measurements depend on sample preparation, calibration, and the compounds included. Estrogen metabolite assays lack universal standardization, so an apparent change across laboratories may partly reflect analytical differences.

What a Trend Can Show

Research using repeated, cycle-timed spot urine samples over two to three years found moderate repeatability for a related 2-pathway hydroxy-to-methoxy ratio. That calculation included an additional methylated estrone product and wasn't this exact 24-hour measurement. It supports studying these patterns over time, but it doesn't establish how large a change in your result is meaningful or whether acting on that change improves health.